Drug Search Results
Using advanced filters...
Advanced Search [+]

Teneligliptin

Alternative Names: teneligliptin, mp-513, mp513, mp 513
Clinical Status: Active
Latest Update: 2025-03-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Argentina | India | Italy | Japan | Korea | Philippines

Approved Indications: None

Known Adverse Events: None

Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Teneligliptin

Countries in Clinic: Korea

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

TERA 304

P3

Completed

Type 2 Diabetes

2024-04-23

52%

2025-01-25

TERA 305

P3

Completed

Type 2 Diabetes

2023-11-30

52%

2025-01-28

Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status